• Combating Antibiotic-Resistant Bacteria Biopharmaceutical Accelerator (CARB-X) has granted $3.96 million to the Center for Vaccine Development and Global Health (CVD) at the University of Maryland School of Medicine.

• This has been granted to develop a maternal vaccine against sepsis caused by Klebsiella pneumoniae in newborns.

• The team is led by Dr. Sharon Tennant, who will collaborate with Auro Vaccines of India.

• The vaccine aims to protect infants by transferring antibodies from vaccinated mothers.

• Neonatal sepsis, a significant cause of infant mortality, especially in low- and middle-income countries, kills 2.5 million infants annually.

• The vaccine could prevent 80-90% of these infections if successful.

• This funding is part of CARB-X's global initiative to combat antibiotic-resistant bacterial infections.

Click here to read more.